Suppr超能文献

来氟米特对系统性红斑狼疮树突状细胞的体外作用及机制的探索性研究

[An exploratory study on in vitro effects and mechanism of leflunomide on dendritic cells of systemic lupus erythematosus].

作者信息

Zhang Xiao, Zhou Hua, Dong Guang-fu, Shi Yun-zhen

机构信息

Department of Rheumatology, Guangdong Provincial People's Hospital, Guangzhou 510080, China.

出版信息

Zhonghua Nei Ke Za Zhi. 2005 May;44(5):370-3.

Abstract

OBJECTIVE

To detect the effects of leflunomide to phenotype and function of dendritic cells (DCs) in systemic lupus erythematosus (SLE) patients, reveal the effective mechanism inducing remission of SLE and lay a research foundation for using 'inhibit' DCs to treat SLE in future.

METHODS

The monocytes were isolated from peripheral blood of SLE patients and cultivated into DCs with cytokines such as GM-CSF and IL-4. A771726 (active metabolite) was added in with cytokines in leflunomide group, but not in control. DCs were harvested after 9 days culture. CD(80), CD(83), CD(86) and HLA-DR surface markers on DCs were detected by flow cytometry (FACS). The ability of DCs stimulating lymphocytes proliferation was detected by MTT assay. IL-10 and IFNgamma level in the supernatant of MLR were detected by ELISA and T cell subtype after MLR was detected by FACS.

RESULTS

The DCs treated with A771726 showed a lower percentage expression of CD(83), CD(86) and HLA-DR phenotype (CD(83): 72.70 +/- 1.77 vs. 79.36 +/- 4.80, CD(86): 63.50 +/- 14.06 vs. 83.91 +/- 9.81, HLA-DR: 80.44 +/- 12.56 vs. 90.51 +/- 8.63, all P < 0.01), a weaker ability to stimulating T lymphocytes proliferation (at DC:TC = 1:10, 0.285 +/- 0.079 vs. 0.458 +/- 0.100; at DC:TC = 1:50, 0.194 +/- 0.054 vs. 0.382 +/- 0.023, all P < 0.01) and a lower secretive level of IL-10 in the MLR supernatant [(195.0 +/- 36.9) microg/L vs. (423.6 +/- 93.2) microg/L, P < 0.01], exclude those it could still increase amount of a new T cell subtype--CD(4)(+)CD(25)(+)CTLA(4)(+) T cell (12.00% & 6.23%).

CONCLUSIONS

A771726 can inhibit DCs maturation, the immature DCs can inhibit T cells proliferation and refrain T cells from dividing into Th(2) subtype, and also the immature DCs can induce a sort of regulate T cell (CD(4)(+)CD(25)(+)CTLA(4)(+) T cell) production. Through that LEF may correct part over humor immune dysfunction and get a new immune balance in SLE.

摘要

目的

检测来氟米特对系统性红斑狼疮(SLE)患者树突状细胞(DCs)表型及功能的影响,揭示其诱导SLE病情缓解的作用机制,为今后应用“抑制”DCs治疗SLE奠定研究基础。

方法

从SLE患者外周血中分离单核细胞,用GM-CSF和IL-4等细胞因子培养成DCs。来氟米特组在细胞因子中加入A771726(活性代谢产物),对照组不加。培养9天后收获DCs。采用流式细胞术(FACS)检测DCs表面CD(80)、CD(83)、CD(86)和HLA-DR标志物。采用MTT法检测DCs刺激淋巴细胞增殖的能力。采用ELISA法检测混合淋巴细胞反应(MLR)上清液中IL-10和IFNγ水平,采用FACS检测MLR后T细胞亚群。

结果

用A771726处理的DCs显示CD(83)、CD(86)和HLA-DR表型的表达百分比降低(CD(83):72.70±1.77对79.36±4.80,CD(86):63.50±14.06对83.91±9.81,HLA-DR:80.44±12.56对90.51±8.63,均P<0.01),刺激T淋巴细胞增殖的能力较弱(在DC:TC=1:10时,0.285±0.079对0.458±0.100;在DC:TC=1:50时,0.194±0.054对0.382±0.023,均P<0.01),MLR上清液中IL-10的分泌水平较低[(195.0±36.9)μg/L对(423.6±93.2)μg/L,P<0.01],除此之外,它仍可增加一种新的T细胞亚群——CD(4)(+)CD(25)(+)CTLA(4)(+)T细胞的数量(12.00%和6.23%)。

结论

A771726可抑制DCs成熟,未成熟的DCs可抑制T细胞增殖并阻止T细胞分化为Th(2)亚群,且未成熟的DCs可诱导产生一种调节性T细胞(CD(4)(+)CD(25)(+)CTLA(4)(+)T细胞)。由此,来氟米特可能纠正SLE部分过度的体液免疫功能紊乱并建立新的免疫平衡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验